Jim Cramer analyzed the impact of President-elect Trump considering Robert F. Kennedy Jr. for Secretary of HHS on the pharmaceutical sector. Cramer believes it presents buying opportunities, as Trump may not let RFK Jr. harm the sector.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing